Indica Labs

06/02/2026

We are looking forward to attending the 22nd European Congress on Digital Pathology in Graz!

Visit us at booth 30 to learn how our industry-leading AI-powered platforms can help you meet your goals and to see live demonstrations of our:

✅ CE-IVDR marked HALO AP enterprise digital pathology platform
✅ HALO Clinical AI tools
✅ HALO platform for quantitative image analysis and research

We look forward to seeing you at !

06/01/2026

🔬 As antibody-drug conjugates continue to expand the precision oncology toolkit, researchers need image analysis solutions capable of generating the quantitative phenotypic and spatial data required to support ADC development.

Join us on June 16 for a preview of the new HALO ADC Target Scoring module, purpose-built for ADC-focused workflows. This webinar will showcase how the module combines:

✅ AI-driven nuclear and membrane segmentation
✅ Enhanced membrane scoring and optical density measurements
✅ Integrated spatial analysis capabilities

During the session, Emily Gamble, HALO Analysis Product Manager, will demonstrate how researchers can move from image analysis to actionable insights through workflows that support quantitative continuous scoring, streamlined data generation, and downstream bioinformatics applications.

Learn more and register today: https://indicalab.com/events/powering-adc-development-with-the-new-halo-adc-target-scoring-module/

05/28/2026

We’re packing our bags for .

If you’ll be attending, be sure to connect with our VP of Precision Medicine, Doug Bowman, to discuss how AI-powered digital pathology is helping shape the future of companion diagnostics and precision oncology. In collaboration with Leica Biosystems, we’re enabling comprehensive CDx co-development that helps transform tissue-level insights into therapeutic strategies with greater confidence.

Want to discuss your project and our solutions? Schedule a meeting here: https://calendly.com/indicalabs/indica-labs-asco

05/27/2026

Precision medicine is rapidly reshaping oncology, and companion diagnostics are now central to ensuring the right therapies reach the right patients.

Indica Labs is proud to announce a major expansion of our CDx capabilities, bringing together quantitative biomarker analysis, AI diagnostics development, and regulatory-ready workflows into a unified offering supporting every stage of development, from discovery through clinical deployment. In collaboration with our partner Leica Biosystems, our Precision Medicine team delivers end-to-end CDx co-development, enabling pharma partners to more rapidly and confidently bring targeted therapies to patients.

Learn more about our expanded CDx offering in our press release: https://indicalab.com/news/press-release/cdx-offering-ahead-of-asco2026/

We invite pharma partners interested in exploring CDx collaboration opportunities to schedule a meeting during ASCO 2026 with Doug Bowman, VP of Precision Medicine: https://calendly.com/indicalabs/indica-labs-asco

Indica Labs unveils its companion diagnostics (CDx) capabilities ahead of 2026 American Society of Clinical Oncology (ASCO)

05/26/2026

Since its first version in 2013, HALO has been setting the standard in quantitative digital pathology, and we’re excited to share what’s coming next.

Join us on June 11 for a first look at version 4.3 of HALO, HALO AI, and HALO Link, where we’ll highlight new capabilities designed to expand workflow flexibility, improve performance, and simplify everyday tasks. In this session, Dr. Noemi Kedei, Director of Product for Life Sciences, will walk through updates including:

✅ Improvements to slide copy workflows supporting future blinded studies
✅ Faster navigation of large-scale projects in HALO Link
✅Customizable object data outputs in HALO
✅ Enhancements to training and classifier pipelines in HALO AI
✅ Expanded user and task management tools for HALO Link administrators

Register to see how these updates can support your next discovery: https://indicalab.com/events/what-is-new-in-halo-halo-ai-and-halo-link-4-3/

11 June 2026 | Learn about the exciting new features in the 4.3 versions of HALO, HALO AI, and HALO Link!

05/26/2026

We are excited to announce our collaboration with Leica Biosystems and Lunit to develop AI-powered image analysis algorithms, focusing on PD-L1 and emerging IHC biomarkers and accelerating precision oncology through scalable and consistent biomarker quantification through computational pathology tools.

The first product will be an AI-powered Lunit SCOPE algorithm designed for research use only with Leica Biosystems’ PD-L1 primary antibody (CAL10), for a combined solution that automates tumor proportion scores (TPS) calculations. This powerful algorithm will be made available through the Aperio AI Store and Aperio HALO AP image management system.

This collaboration brings together the Aperio HALO AP image management system powered by Indica Labs, Leica Biosystems’ PD-L1 IHC assay platform, Aperio GT 450 digital pathology scanner, and Lunit SCOPE biomarker scoring algorithm, reflecting a shared commitment to open-pathology and interoperability. As our CEO, Steven Hashagen, notes, “robust end-to-end solutions like these are a critical step toward realizing the promise of AI in digital pathology.”

Read our press release to learn more about the partnership and its goals: https://indicalab.com/news/press-release/pd-l1-and-emerging-biomarkers/

Lunit SCOPE PD-L1 CAL10 algorithm and PD-L1 CAL10 assay are for research use only. Not for use in diagnostic procedures.

Indica Labs, Leica Biosystems, and Lunit will focus on PD-L1 and emerging immunohistochemistry (IHC) biomarkers, for precision oncology.

05/22/2026

📆 We're counting down the days to and are excited to have our own Dr. Ghislaine Lioux, Senior Field Applications Scientist, present on an AI-powered image analysis pipeline to profile TLS at single-cell resolution.

Drop by Ghislaine's poster on the 9th to learn how this workflow offers a scalable approach for high-dimensional tissue analysis that combines deep learning, supervised classification, and data-driven discovery. We look forward to seeing you in Budapest!

05/21/2026

Antibody-drug conjugate assays are reshaping targeted therapies, but accurate, quantitative image analysis is required to inform ADC development and response prediction. Providing researchers with the latest tools to meet this challenge, we're excited to share a sneak peek webinar introducing the new HALO module designed to streamline analysis for ADC-focused assays, the ADC Target Scoring module.

This new module enables quantitative continuous scoring (QCS) strategies and provides users with the rich data needed for bioinformatic pipelines by integrating:

✅ AI-powered membrane and nuclear segmentation
✅ Expanded membrane compartment detection and OD metrics
✅ Built-in spatial analysis

Join us on 16 June as Emily Gamble, HALO Analysis Product Manager, explores how this powerful new module bridges image analysis and downstream data interpretation, and walks through a complete workflow in HALO, from cell segmentation and Threshold Assist to customizable outputs and result visualization.

Learn more and register today: https://indicalab.com/events/powering-adc-development-with-the-new-halo-adc-target-scoring-module/

05/21/2026

If you'll be at the European Association for Cancer Research's , we look forward to connecting with you!

Jeff Dzubay, Senior Director of Business Development for Pharma Services, and Dr. Ghislaine Lioux, Senior Field Applications Scientist, will be in Budapest to discuss how our HALO platforms and Pharma Services are powering oncology research and precision medicine.

Looking to streamline your quantitative image analysis and unlock deeper insights into your WSI? Interested in partnering to leverage Pharma Services' image analysis and AI expertise to advance your biomarker project? Chat with Ghislaine and Jeff to learn how our platforms and services can help you meet your goals.

Want to schedule a 1:1 meeting that fits your calendar? Follow the link to select a time that works for you: https://calendly.com/indicalabs/indica-labs-european-association-for-cancer-research-2026

05/19/2026

Interested in advancing your ISH image analysis workflows? Join our upcoming collaborative webinar with Bio-Techne Spatial to explore the latest RNAscope assays and how HALO supports analysis across both brightfield and fluorescence imaging.

Led by Indica Labs’ Spencer Revill and Bio-Techne Spatial’s Anushka Dixit, Ph.D., this session will include a live walkthrough of HALO’s ISH and FISH modules, demonstrate how HALO AI improves segmentation and tissue classification, and highlight key capabilities such as TMA and spatial analysis.

Register to learn practical approaches for building more efficient, scalable RNAscope analysis workflows: https://lnkd.in/giRsCh2U